In adults who had not had COVID-19, Novavax vaccine had 90% efficacy at ≥7 d after the second dose.
Where this comes from
- Record sourced from PubMed, PMID 35500261.
- Also identified by DOI 10.7326/J22-0028.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Dunkle LM, Kotloff KL, Gay CL, et al. <b>Efficacy and safety of NVX-CoV2373 in adults in the United States and Mexico.</b> N Engl J Med. 2022;386:531-43. 34910859.
Medical subject headings
- COVID-19
- Vaccines